Article Text

Download PDFPDF

Methylprednisolone injection improved symptoms for 1 year in patients with the carpal tunnel syndrome
  1. Herman Weinreb, MD
  1. New York University Medical Center New York, New York, USA

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: What is the effectiveness of a methylprednisolone injection in patients with the carpal tunnel syndrome?


    Randomised (allocation concealed*), blinded (clinician, patient, and outcome assessor),* placebo controlled trial with 1 year follow up.


    Outpatient neurology clinic in a district general hospital in the Netherlands.


    Patients >18 years of age (mean age 52 y, 83% women) who had signs and symptoms of the carpal tunnel syndrome for ≥3 months confirmed by electrophysiological tests. Patients who had already been treated for the carpal tunnel syndrome were excluded. Follow up was 100%.


    Patients were allocated to receive a single injection of methylprednisolone, 40 mg, and lignocaine, 10 mg (intervention group, n=30), or lignocaine, 10 mg, alone (control group, n=30) proximal to the carpal tunnel. In patients with bilateral symptoms, the arm with the most severe symptoms was included in the study.

    Main outcome measures

    Symptom improvement was defined as having no symptoms or minor symptoms requiring no further treatment at 1 month. Patients were also evaluated at 3, 6, 9, and 12 months.

    Main results

    More patients in the intervention group had symptom improvement than did those in the control group at 1, 3, 6, 9, and 12 months (p<0.01) (table).

    Methylprednisolone injection v control for symptom improvement in patients with the carpal tunnel syndrome†


    In patients with the carpal tunnel syndrome, an injection of methylprednisolone was effective in improving symptoms for up to 1 year.


    This rigorous study by Dammers and colleagues of the benefits of methylprednisolone in the non-surgical management of the carpal tunnel syndrome used a methodologically sound design to show that 1 injection of methylprednisolone may prevent the need for surgical decompression in 43% of patients at 1 year.

    Injections into the carpal tunnel have traditionally been used as a temporary solution. Previous studies of corticosteroid injections in managing the carpal tunnel syndrome have used an uncontrolled series design. 1 study examined 497 patients who were treated with steroid injections; of these, 14% reported no further symptoms, 12% improved, and 26% eventually required surgery.1 Another study examined the benefit of injections in 50 hands among 41 patients with a mean follow up of 18 months.2 At the conclusion of this study, 22% of the 50 hands were free of symptoms. Patients with minimal or intermittent symptoms and negative physical examinations had the highest success rate, whereas patients with persistent numbness or thenar atrophy had the lowest success rate. Yet another study reported that injections gave complete relief of all symptoms in 30% to 40% of patients, with relief lasting from several weeks to 6 months; a further 10% to 20% of patients gained partial benefit from injection, although most of these patients eventually needed surgery.3 Dammers and colleagues do not report how many patients eventually went on to surgery, but we might assume that the patients who did not respond to steroid therapy became surgical candidates.

    Methylprednisolone injection into the carpal tunnel is strictly a one time procedure. Repeated injections carry the risk for tendon rupture and nerve damage. The technique is easily learned but should be mastered through hands on training with an experienced operator.


    View Abstract


    • Source of funding: no external funding.

    • For correspondence: Dr J W Dammers, Department of Neurology, Medical Centre Alkmaar, PO Box 501, 1800 AM Alkmaar, the Netherlands.

    • * See glossary.